Limited Fibrosis Progression but Significant Mortality in Patients Ineligible for Interferon-Based Hepatitis C...

Area of Science:

• Hepatology
• Viral Hepatitis
• Clinical Outcomes Research

Background:

• Hepatitis C (HCV) patients ineligible for interferon-based therapy may experience poorer prognoses.
• Understanding treatment limitations in real-world HCV populations is crucial.

Purpose of the Study:

• To investigate the limitations of medical treatment for hepatitis C in a real-world patient cohort.
• To analyze factors influencing prognosis and survival in treatment-ineligible HCV patients.

Main Methods:

• A cohort study of 969 treatment-ineligible and 403 treated hepatitis C patients (2001-2006, follow-up to 2013).
• Categorization of treatment barriers (health-related vs. health-unrelated) and assessment of fibrosis progression.
• Mortality data obtained via Social Security database searches and death certificate reviews.

Main Results:

• Health-related treatment barriers correlated with increased fibrosis progression and reduced survival.
• Among untreated patients, 53% of deaths were from non-liver-related causes.
• Significant comorbid illness predicted disease progression and was associated with the worst 5- and 10-year survival rates (70% and 50.5%, respectively).
• Treated patients demonstrated superior 10-year survival compared to untreated patients (80.3% vs. 74.5%).

Conclusions:

• A substantial proportion of hepatitis C patients succumb to non-liver-related causes.
• Current antiviral treatments may not benefit all hepatitis C patients, particularly those with significant comorbidities.